The Defence Select Committee has today published its long-awaited report on the use of Lariam as an anti-malarial drug by the Ministry of Defence.
The report is highly critical of the MOD over the way that is has issued the drug, in particular in relation to the lack of individual risk assessments beforehand, as required by the drug’s manufacturer, Roche. It is estimated that up to 35% of service personnel have suffered psychological and psychiatric side effects, such as anxiety, nightmares, and depression. In some cases, the symptoms have been severe and have led to a medical discharge, loss of a valued career and pension. A number of legal claims will now be brought.